These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 27220900)

  • 1. Efficacy of the GemOx-R regimen leads to the identification of Oxaliplatin as a highly effective drug against Mantle Cell Lymphoma.
    Obrador-Hevia A; Serra-Sitjar M; Rodríguez J; Belayachi L; Bento L; García-Recio M; Sánchez JM; Villalonga P; Gutiérrez A; Fernández de Mattos S
    Br J Haematol; 2016 Sep; 174(6):899-910. PubMed ID: 27220900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab, gemcitabine and oxaliplatin in relapsed or refractory indolent and mantle cell lymphoma: results of a multicenter phase I/II-study of the German Low Grade Lymphoma Study Group.
    Scheubeck G; Hoffmann M; Jurinovic V; Fischer L; Unterhalt M; Schmidt C; Böck HP; Dührsen U; Kaesberger J; Kremers S; Lindemann HW; Mantovani L; Hiddemann W; Hoster E; Dreyling M;
    Ann Hematol; 2024 Jul; 103(7):2373-2380. PubMed ID: 38459156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab, gemcitabine and oxaliplatin: an effective regimen in patients with refractory and relapsing mantle cell lymphoma.
    Rodríguez J; Gutierrez A; Palacios A; Navarrete M; Blancas I; Alarcón J; Caballero MD; De Mattos SF; Gines J; Martínez J; Lopez A
    Leuk Lymphoma; 2007 Nov; 48(11):2172-8. PubMed ID: 17990179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy and safety evaluation of gemcitabine combined with oxaliplatin in lymphoma patients after failure of multiple chemotherapy regimens].
    Yang J; Shi Y; He X; Zhou S; Dong M; Liu P; Zhang C; Qin Y; Yang S; Gui L
    Zhonghua Zhong Liu Za Zhi; 2014 Feb; 36(2):137-40. PubMed ID: 24796464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study.
    López A; Gutiérrez A; Palacios A; Blancas I; Navarrete M; Morey M; Perelló A; Alarcón J; Martínez J; Rodríguez J
    Eur J Haematol; 2008 Feb; 80(2):127-32. PubMed ID: 18005385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemcitabine-oxaliplatin plus rituximab (R-GemOx) as first-line treatment in elderly patients with diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 trial.
    Shen QD; Zhu HY; Wang L; Fan L; Liang JH; Cao L; Wu W; Xia Y; Li JY; Xu W
    Lancet Haematol; 2018 Jun; 5(6):e261-e269. PubMed ID: 29752199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma.
    Corazzelli G; Capobianco G; Arcamone M; Ballerini PF; Iannitto E; Russo F; Frigeri F; Becchimanzi C; Marcacci G; De Chiara A; Pinto A
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):907-16. PubMed ID: 19219604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxaliplatin-based chemotherapy (dexamethasone, high-dose cytarabine, and oxaliplatin)±rituximab is an effective salvage regimen in patients with relapsed or refractory lymphoma.
    Rigacci L; Fabbri A; Puccini B; Chitarrelli I; Chiappella A; Vitolo U; Levis A; Lauria F; Bosi A
    Cancer; 2010 Oct; 116(19):4573-9. PubMed ID: 20572029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy.
    El Gnaoui T; Dupuis J; Belhadj K; Jais JP; Rahmouni A; Copie-Bergman C; Gaillard I; Diviné M; Tabah-Fisch I; Reyes F; Haioun C
    Ann Oncol; 2007 Aug; 18(8):1363-8. PubMed ID: 17496309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents.
    Klanova M; Lorkova L; Vit O; Maswabi B; Molinsky J; Pospisilova J; Vockova P; Mavis C; Lateckova L; Kulvait V; Vejmelkova D; Jaksa R; Hernandez F; Trneny M; Vokurka M; Petrak J; Klener P
    Mol Cancer; 2014 Jun; 13():159. PubMed ID: 24972933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemcitabine and oxaliplatinum: an effective regimen in a patient with progressive refractory mantle cell lymphoma.
    Sampol A; Rodriguez J; Galmés B; Gutierrez A; Besalduch J
    Leuk Lymphoma; 2004 Jun; 45(6):1289-91. PubMed ID: 15360015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab, Ara-C, dexamethasone and oxaliplatin (R-ADOx) is effective for treatment of elderly patients with relapsed mantle cell lymphoma.
    Lamm W; Drach J; Kiesewetter B; Zielinksi CC; Mayerhöfer ME; Müllauer L; Raderer M
    J Cancer Res Clin Oncol; 2013 Oct; 139(10):1771-5. PubMed ID: 23873598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. (R)-GEMOX chemotherapy for unfit patients with refractory or recurrent primary central nervous system lymphoma: a LOC study.
    Collignon A; Houillier C; Ahle G; Chinot O; Choquet S; Schmitt A; Agape P; Soussain C; Hoang-Xuan K; Tabouret E
    Ann Hematol; 2019 Apr; 98(4):915-922. PubMed ID: 30535802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of SAMHD1 expression and mutation status in mantle cell lymphoma: An analysis of the MCL Younger and Elderly trial.
    Roider T; Wang X; Hüttl K; Müller-Tidow C; Klapper W; Rosenwald A; Stewart JP; de Castro DG; Dreger P; Hermine O; Kluin-Nelemans HC; Grabe N; Dreyling M; Pott C; Ott G; Hoster E; Dietrich S
    Int J Cancer; 2021 Jan; 148(1):150-160. PubMed ID: 32638373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau.
    Eskelund CW; Kolstad A; Jerkeman M; Räty R; Laurell A; Eloranta S; Smedby KE; Husby S; Pedersen LB; Andersen NS; Eriksson M; Kimby E; Bentzen H; Kuittinen O; Lauritzsen GF; Nilsson-Ehle H; Ralfkiaer E; Ehinger M; Sundström C; Delabie J; Karjalainen-Lindsberg ML; Workman CT; Garde C; Elonen E; Brown P; Grønbaek K; Geisler CH
    Br J Haematol; 2016 Nov; 175(3):410-418. PubMed ID: 27378674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome for patients with relapsed/refractory aggressive lymphoma treated with gemcitabine and oxaliplatin with or without rituximab; a retrospective, multicentre study.
    Dhanapal V; Gunasekara M; Lianwea C; Marcus R; De Lord C; Bowcock S; Devereux S; Patten P; Yallop D; Wrench D; Fields P; Kassam S
    Leuk Lymphoma; 2017 Sep; 58(9):1-9. PubMed ID: 28093003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab, dexamethasone, cytarabine, and oxaliplatin (R-DHAX) is an effective and safe salvage regimen in relapsed/refractory B-cell non-Hodgkin lymphoma.
    Lignon J; Sibon D; Madelaine I; Brice P; Franchi P; Briere J; Mounier N; Gisselbrecht C; Faure P; Thieblemont C
    Clin Lymphoma Myeloma Leuk; 2010 Aug; 10(4):262-9. PubMed ID: 20709662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sintilimab plus GemOx is an effective salvage therapy in patients with refractory/relapsing nodal peripheral T cell lymphomas.
    Xiao X; Hu M; Jiang H; Chen P; Lei H
    J Cancer Res Clin Oncol; 2024 Sep; 150(9):425. PubMed ID: 39299973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A New Salvage Regimen for Aggressive Lymphomas Based on Gemcitabine, Rituximab, and Oxaliplatin Followed by Lenalidomide (GROC-Rev).
    Cabanillas F; Rivera N; Acosta M; Pardo W; Solivan P; Rivera C; Liboy I
    Clin Lymphoma Myeloma Leuk; 2019 Dec; 19(12):776-783. PubMed ID: 31591042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemox: a widely useful therapy against solid tumors-review and personal experience.
    Meriggi F; Zaniboni A
    J Chemother; 2010 Oct; 22(5):298-303. PubMed ID: 21123151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.